Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Abstract
Apoptosis is a genetically encoded programme of cell death that can be activated under physiological conditions and may be an important safeguard against tumour development. Regions of low oxygen (hypoxia) and necrosis are common features of solid tumours. Here we report that hypoxia induces apoptosis in oncogenically transformed cells and that further genetic alterations, such as loss of the p53 tumour-suppressor gene or overexpression of the apoptosis-inhibitor protein Bcl-2, substantially reduce hypoxia-induced cell death. Hypoxia also selects for cells with defects in apoptosis, because small numbers of transformed cells lacking p53 overtake similar cells expressing wild-type p53 when treated with hypoxia. Furthermore, highly apoptotic regions strongly correlate with hypoxic regions in transplanted tumours expressing wild-type p53, whereas little apoptosis occurs in hypoxic regions of p53-deficient tumours. We propose that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53 mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Giaccia and co-workers demonstrated that hypoxia can induce tumor cell apoptosis, an effect that was reduced by loss of p53 tumor suppressor function or overexpression of anti-apoptotic Bcl-2 (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Therefore, hypoxia can exert a selective pressure that leads to expansion of tumor cells with reduced apoptotic capacity due to, for example, TP53 mutations (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Hypoxia and/or HIFs can mediate chemotherapy resistance through additional mechanisms including: a) hypoxia-induced decreases in tumor cell proliferation (Tannock, 1968); b) metabolic reprogramming; c) hypoxia-driven selection of p53-mutated tumor cells with less apoptotic capacity (Graeber et al., 1996); and d) inhibition of DNA damage (Sullivan & Graham, 2009).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
The Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Sunburn and p53 in the onset of skin cancer
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., & Brash, D. E. (1994) · Nature · doi:10.1038/372773a0 · Cited by 1,497
Self-citation
Research works printed but not linked: 9
- Vaupel, P. W. & Hockel, M. in Tumor Oxygenation (eds Vaupel, P. W., Kelleher, D. K. & Gunderoth, M.) 219–232 (Gustav Fischer, Stuttgart, 1995).
- Lord, E. M., Harwell, L. & Koch, C. J. Cancer Res. 53, 5721–5726 (1993).
- Bardeesy, N., Beckwith, J. B. & Pelletier, J. Cancer Res. 55, 215–219 (1995).
- Baker, S. J. et al. Cancer Res. 50, 7717–7722 (1990).
- Sinicrope, F. A. et al. Cancer Res. 55, 237–241 (1995).
- Bedi, A. et al. Cancer Res. 55, 1811–1816 (1995).
- Lotem, J. & Sachs, L. Cell Growth. Differ. 4, 41–47 (1993).
- Lowe, S. W. Curr. Opin. Oncol. (in the press).
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 401–500 of 1,006
Conventional cancer therapy: promise broken or promise delayed?
Tannock, I. F. (1998) · The Lancet · doi:10.1016/s0140-6736(98)90327-0 · Cited by 191
Mechanisms of Hypoxia-induced Endothelial Cell Death
Stempien‐Otero, A., Karsan, A., Cornejo, C. J., Xiang, H., Eunson, T., Morrison, R. S., Kay, M. A., Winn, R. K., & Harlan, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8039 · Cited by 177
Cancer invasion and resistance: interconnected processes of disease progression and therapy failure
Alexander, S., & Friedl, P. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.11.003 · Cited by 182
Dysregulation of apoptosis genes in hematopoietic malignancies
Kitada, S., Pedersen, I. M., Schimmer, A. D., & Reed, J. C. (2002) · Oncogene · doi:10.1038/sj.onc.1205327 · Cited by 176
“…also play roles in tumor resistance to hypoxia, growth factor deprivation, immune surveillance mechanisms, chemotherapy, radiation, and other selective pressures (Graeber et al., 1996; Makin and Hickmann, 2000; Medh and Thompson, 2000; Rinkenberger and Korsmeyer, 1997; Strasser et al., 1997).”
BackgroundMorphologic Instability and Cancer Invasion
Cristini, V., Frieboes, H. B., Gatenby, R., Caserta, S., Ferrari, M., & Sinek, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0852 · Cited by 163
West, C. (1997) · International Journal of Radiation Biology · doi:10.1080/095530097143716 · Cited by 159
Radiation effects on the tumor microenvironment: Implications for nanomedicine delivery
Stapleton, S., Jaffray, D. A., & Milosevic, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.021 · Cited by 168
Li, H., Rokavec, M., Jiang, L., Horst, D. A., & Hermeking, H. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.017 · Cited by 166
Control of the hypoxic response through regulation of mRNA translation
Wouters, B. G., van den Beucken, T., Magagnin, M. G., Koritzinsky, M., Fels, D. R., & Koumenis, C. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2005.03.009 · Cited by 177
Comito, G., Calvani, M., Giannoni, E., Bianchini, F., Calorini, L., Torre, E., Migliore, C., Giordano, S., & Chiarugi, P. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.042 · Cited by 168
Early stages of p53-induced apoptosis are reversible
Geske, F. J., Lieberman, R., Strange, R., & Gerschenson, L. E. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400786 · Cited by 159
Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma
Ács, G., Zhang, P. J., Rebbeck, T. R., Acs, P. I., & Verma, A. M. (2002) · Cancer · doi:10.1002/cncr.10787 · Cited by 167
“It is believed that hypoxia mediates the selection of neoplastic cells with diminished apoptotic potential by providing a growth advantage to cells with genetic alterations that impair the process of apoptosis.(66) This hypoxia-mediated clonal selection of tumor cells with diminished apoptotic potential has been sugge…”
BackgroundMiyake, K., Yoshizumi, T., Imura, S., Sugimoto, K., Batmunkh, E., Kanemura, H., Morine, Y., & Shimada, M. (2008) · Pancreas · doi:10.1097/mpa.0b013e31815f2c2a · Cited by 155
Lu, H., Fisher, R. P., Bailey, P., & Levine, A. J. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.10.5923 · Cited by 152
“Although it is known that p53 is activated and stabilized by damaged DNA (35), hypoxia ( 25 ), or a lower level of ribonucleoside triphosphates (43), it remains unclear how this happens.”
BackgroundCuvier, C., Jang, A., & Hill, R. P. (1997) · Clinical & Experimental Metastasis · doi:10.1023/a:1018428105463 · Cited by 169
“More recently it has been reported that exposure of tumor cells to hypoxia in vivo may accelerate tumor progression because cells containing a mutant p53 gene are more resistant to the induction of cell death (apoptosis) by such exposures [12].”
BackgroundConcepts of oxygen transport at the microcirculatory level
Dewhirst, M. W. (1998) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(98)80040-4 · Cited by 158
Targeting the Metabolic Microenvironment of Tumors
Bailey, K. M., Wojtkowiak, J. W., Hashim, A. I., & Gillies, R. J. (2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-397927-8.00004-x · Cited by 154
“It is hypothesized that hypoxiamediated inhibition of mTOR is a selective mechanism for mutations that are beneficial for cell growth in hostile environments (Graeber et al., 1996).”
BackgroundMelanoma × macrophage hybrids with enhanced metastatic potential
Rachkovsky, M., Sodi, S., Chakraborty, A. K., Avissar, Y. J., Bolognia, J. L., McNiff, J. M., Platt, J. T., Bermudes, D. G., & Pawelek, J. M. (1998) · Clinical & Experimental Metastasis · doi:10.1023/a:1006557228604 · Cited by 154
“Solid tumors are irregularly vascularized and hypoxic, with large necrotic areas rich in apoptotic cells [98], conditions shown to select for survival of cells with diminished apoptotic potential in solid tumors [99].”
BackgroundFerredoxin reductase is critical for p53-dependent tumor suppression via iron regulatory protein 2
Zhang, Y., Qian, Y., Zhang, J., Yan, W., Jung, Y.-S., Chen, M., Huang, E., Lloyd, K., Duan, Y., Wang, J., et al. (2017) · Genes & Development · doi:10.1101/gad.299388.117 · Cited by 151
“…activated in response to an array of stresses, such as DNA damage (Nelson and Kastan 1994), oncogene activation (Lowe and Ruley 1993), and hypoxia (Graeber et al. 1996). p53 transcriptional activity is also modulated by cellular redox state and the abundance of ADP and iron in response to altered…”
Wouters, A., Pauwels, B., Lardon, F., & Vermorken, J. B. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-690 · Cited by 147
“Third, it has been hypothesized that hypoxia creates a selective pressure for tumors, allowing the expansion of cell subpopulations that have lost their apoptotic potential, in particular cell variants that have acquired p53 mutations [ 107 ].”
BackgroundIrradiation selects for p53-deficient hematopoietic progenitors.
Marusyk, A., Porter, C. C., Zaberezhnyy, V., & DeGregori, J. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000324 · Cited by 151
“Within established tumors, chemotherapy leading to DNA damage and anti-angiogenic therapy leading to hypoxia have each been shown to potently select for p53 disruption [24,46,47].”
BackgroundMesenchymal stem cells and hypoxia: Where are we?
Buravkova, L. B., Andreeva, E. R., Gogvadze, V. G., & Zhivotovsky, B. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.07.005 · Cited by 157
Reshkin, S. J., Bellizzi, A., Albarani, V., Guerra, L., Tommasino, M., Paradiso, A., & Casavola, V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5361 · Cited by 153
Hypoxia and anemia: effects on tumor biology and treatment resistance
Vaupel, P. W., & Mayer, A. (2005) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2004.11.005 · Cited by 171
p53-Mediated Germ Cell Quality Control in Spermatogenesis
Yin, Y., Stahl, B. C., DeWolf, W. C., & Morgentaler, A. (1998) · Developmental Biology · doi:10.1006/dbio.1998.9074 · Cited by 174
Dissecting the pathways to death
Daniel, P. (2000) · Leukemia · doi:10.1038/sj.leu.2401940 · Cited by 165
Expression of apoptosis regulators in cutaneous malignant melanoma.
Tang, L., Tron, V. A., Reed, J. C., Mah, K., Krajewska, M., Li, G., Xin Min, Z. H. O. U., Ho, V. C., & Trotter, M. J. (1998) · PubMed · Cited by 152
VEGF deprivation-induced apoptosis is a component of programmed capillary regression
Meeson, A. P., Argilla, M., Ko, K., Witte, L., & Lang, R. A. (1999) · Development · doi:10.1242/dev.126.7.1407 · Cited by 146
Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress
Hasmim, M., Messai, Y., Ziani, L., Thiery, J., Bouhris, J.-H., Noman, M. Z., & Chouaïb, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00482 · Cited by 160
“Tumor hypoxia is a negative prognostic and predictive factor due to many effects on the selection of hypoxia-surviving clones (59), activation of the expression of genes involved in apoptosis inhibition (60), angiogenesis (61), invasiveness and metastasis (62), epithelial-to-mesenchymal transition (63), and loss of ge…”
BackgroundImmunogenic ferroptosis and where to find it?
Demuynck, R., Efimova, I., Naessens, F., & Krysko, D. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003430 · Cited by 167
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Gruber, G., Greiner, R. H., Hlushchuk, R., Aebersold, D. M., Altermatt, H. J., Berclaz, G., & Djonov, V. (2004) · Breast Cancer Research · doi:10.1186/bcr775 · Cited by 144
“Discussion Findings over the past few years indicate that genetically modified cells [11] with an enhanced metastatic potential [12] and those with diminished apoptosis [13] selectively survive under hypoxic conditions, and that hypoxia may be Available online http://breast-cancer-research.”
BackgroundUp-regulation of Apoptosis Inhibitory Protein IAP-2 by Hypoxia
Dong, Z., Venkatachalam, M. A., Wang, J., Patel, Y., Saikumar, P., Semenza, G. L., Force, T., & Nishiyama, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011774200 · Cited by 150
Strategies for manipulating the p53 pathway in the treatment of human cancer
Hupp, T. R., Lane, D. P., & Ball, K. L. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3520001 · Cited by 148
Divergent mutational processes distinguish hypoxic and normoxic tumours
Bhandari, V., Li, C. H., Bristow, R. G., Boutros, P. C., PCAWG Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14052-x · Cited by 142
Hypoxia Inhibits Myogenic Differentiation through Accelerated MyoD Degradation
Di Carlo, A., De Mori, R., Martelli, F., Pompilio, G., Capogrossi, M. C., & Germani, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313931200 · Cited by 142
Jing, X., Hu, H., Sun, Y., Yu, B., Cong, H., & Shen, Y. (2022) · Small Methods · doi:10.1002/smtd.202101437 · Cited by 153
Translational control of gene expression during hypoxia
van den Beucken, T., Koritzinsky, M., & Wouters, B. G. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2972 · Cited by 142
Antiangiogenesis for cancer therapy
Harris, A. L. (1997) · The Lancet · doi:10.1016/s0140-6736(97)90014-3 · Cited by 145
Hypoxia-induced genetic instability—a calculated mechanism underlying tumor progression
Huang, E. L., Bindra, R. S., Glazer, P. M., & Harris, A. L. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0133-6 · Cited by 159
“Conversely, p53 mutated cells with diminished apoptotic potential are selected by tumor hypoxia [76].”
Carson, J. P., Kulik, G., & Weber, M. J. (1999) · PubMed · Cited by 162
Conditional Mutation of Rb Causes Cell Cycle Defects without Apoptosis in the Central Nervous System
MacPherson, D., Sage, J., Crowley, D., Trumpp, A., Bronson, R. T., & Jacks, T. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.3.1044-1053.2003 · Cited by 143
“Importantly, hypoxia treatment of oncogenically transformed MEFs in vitro led to selection for cells with mutated p53 (15).”
BackgroundInfluentialSelf-citationRecent developments in the regulation of the angiogenic switch by cellular stress factors in tumors
North, S., Moenner, M., & Bikfalvi, A. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.08.007 · Cited by 113
“[41] T.”
BackgroundpH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents
Andreev, O. A., Engelman, D. M., & Reshetnyak, Y. K. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.509285 · Cited by 151
“…tumour cell survival in acidic conditions via selection of cells that are resistant to acid-induced cell toxicity and hypoxia-induced, p53-dependent apoptosis (Graeber et al. 1996, Park et al. 1999, Williams et al. 1999, Gatenby et al. 2007), and promote invasiveness by killing normal tissue cells.”
Alarcon, R. M., Koumenis, C., Geyer, R. K., Maki, C. G., & Giaccia, A. J. (1999) · PubMed · Cited by 170
Self-citationRodríguez-Enríquez, S., Carreño-Fuentes, L., Gallardo-Pérez, J. C., Saavedra, E., Quezada, H., Vega, A., Marín-Hernández, A., Olín-Sandoval, V., Torres-Márquez, M. E., & Moreno-Sánchez, R. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.07.010 · Cited by 142
Cheng, C.-W., Kuo, C.-Y., Fan, C.-C., Fang, W.-C., Jiang, S. S., Lo, Y.-K., Wang, T.-Y., Kao, M.-C., & Lee, A. Y.-L. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.204 · Cited by 141
Prospective therapeutic applications of p53 inhibitors
Gudkov, A. V., & Komarova, E. A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.153 · Cited by 155
Patterson, D. M., & Rustin, G. J. S. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.03.014 · Cited by 146
Chafe, S. C., Vizeacoumar, F. S., Venkateswaran, G., Nemirovsky, O., Awrey, S. J., Brown, W. S., McDonald, P. C., Carta, F., Metcalfe, A. L., Karasinska, J. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj0364 · Cited by 147
Hypoxia Inducible Factor Pathway Inhibitors as Anticancer Therapeutics
Burroughs, S. K., Kaluz, S., Wang, D., Wang, K., Van Meir, E. G., & Wang, B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.17 · Cited by 140
Rubin, M. A., Bristow, R. G., Thienger, P., Dive, C., & Imielinski, M. B. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.033 · Cited by 147
Yin, H., Lee, G.-I., Sedey, K. A., Rodriguez, J. M., Wang, H.-G., Sebti, S. M., & Hamilton, A. D. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0446404 · Cited by 137
The hypoxia factor Hif-1α controls neural crest chemotaxis and epithelial to mesenchymal transition
Barriga, E. H., Maxwell, P. H., Reyes, A. E., & Mayor, R. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201212100 · Cited by 138
Effects of hypoxia on human cancer cell line chemosensitivity
Strese, S., Fryknäs, M., Larsson, R., & Gullbo, J. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-331 · Cited by 136
“Hypoxia also selects for cells with low expression of p53 and consequently p53-induced apoptosis is reduced in hypoxic cells [19].”
BackgroundFluorinated tracers for imaging cancer with positron emission tomography
Couturier, O., Luxen, A., Chatal, J.-F., Vuillez, J.-P., Rigo, P., & Hustinx, R. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1607-9 · Cited by 165
Nickel-induced transformation shifts the balance between HIF-1 and p53 transcription factors
Salnikow, K., An, W. G., Melillo, G., Blagosklonny, M. V., & Costa, M. (1999) · Carcinogenesis · doi:10.1093/carcin/20.9.1819 · Cited by 139
The p53 protein family and radiation sensitivity: Yes or no?
Cuddihy, A. R., & Bristow, R. G. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031764.81141.e4 · Cited by 153
“In experimental models, severe intratumoral hypoxia appeared to apply selective pressure for the survival of genetically unstable MTp53-expressing tumor cells that might partially explain hypoxia-mediated resistance to therapy and increased metastases [153].”
Backgroundp53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice
Mizuno, S., Bogaard, H. J., Kraskauskas, D., Alhussaini, A. A., Gomez‐Arroyo, J. G., Voelkel, N. F., & Ishizaki, T. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00286.2010 · Cited by 136
“In tumors expressing wild-type (WT) p53, hypoxic cells undergo apoptosis strongly correlated with the hypoxic regions, whereas tumors expressing mutant p53 exhibit lower levels of apoptosis in hypoxic regions (17).”
BackgroundCirculating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype
Ameri, K., Luong, R. H., Zhang, H., Powell, A. A., Montgomery, K. D., Espinosa, Í., Bouley, D. M., Harris, A. L., & Jeffrey, S. S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605491 · Cited by 148
“Tumours are heterogeneous and contain regions of hypoxia and anoxia, which may select for cells with more aggressive phenotypes and diminished apoptotic potential (Graeber et al, 1996; Zhang and Hill, 2004).”
BackgroundBedogni, B., & Powell, M. B. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00553.x · Cited by 131
“Because stringent hypoxia ⁄ anoxia (<0.5% O2) is toxic for normal and tumor cells, it can promote tumor progression by selecting cells with mutations that allow them to survive in these extreme conditions (Graeber et al., 1996; Hammond et al., 2007).”
BackgroundInfluentialGiatromanolaki, A., Koukourakis, M. I., Sowter, H. M., Sivridis, E., Gibson, S., Gatter, K. C., & Harris, A. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0076 · Cited by 136
“(21) is that hypoxia can act to select tumor cell populations that are better able to survive under an unfavorable microenvironment, to migrate, and contribute to greater aggression, which contributes to poor prognosis.”
BackgroundHypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT
Leszczynska, K. B., Foskolou, I. P., Abraham, A. G., Anbalagan, S., Tellier, C., Haider, S., Span, P. N., O’Neill, E. E., Buffa, F. M., & Hammond, E. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80402 · Cited by 133
“Previous studies have demonstrated that hypoxia-induced p53 is proapoptotic and suggest that this is the primary role for p53 in hypoxia (11, 18, 21).”
BackgroundHypoxia Tolerance in Animals: Biology and Application
Gorr, T. A., Wichmann, D., Hu, J., Hermes‐Lima, M., Welker, A. F., Terwilliger, N., Wren, J. F., Viney, M., Morris, S., Nilsson, G. E., et al. (2010) · Physiological and Biochemical Zoology · doi:10.1086/648581 · Cited by 134
“These HIF-independent pathways often center on the tumor suppressor protein p53, the known gatekeeper for cell cycle arrest or apoptosis in DNA-damaged, deoxygenated, and nucleoside triphosphate–depleted cells (Graeber et al. 1996; An et al. 1998; Wenger et al. 1998).”
BackgroundPani, G., Bedogni, B., Anzevino, R., Colavitti, R., Palazzotti, B., Borrello, S., & Galeotti, T. (2000) · PubMed · Cited by 145
The CXCL12–CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies
Epstein, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1473 · Cited by 146
“70 ) provides a candidate explanation for the apoptotic resistance of ischaemic tumour”
BackgroundPolarographic electrode study of tumor oxygenation in clinically localized prostate cancer
Parker, C. C., Milosevic, M., Toi, A., Sweet, J., Panzarella, T., Bristow, R. G., Catton, C., Catton, P. A., Crook, J. M., Gospodarowicz, M. K., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)01621-3 · Cited by 134
Heterogeneous Vascular Dependence of Tumor Cell Populations
Yu, J., Rak, J. W., Carmeliet, P., Nagy, A., Kerbel, R. S., & Coomber, B. L. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64083-7 · Cited by 150
“The concept of vascular dependence therefore potentially encompasses a broad range of cellular functions, in particular cell proliferation and cell survival under conditions of metabolic stress such as hypoxia and hypoglycemia, as well as responses to endothelial cell-derived paracrine signals.(19,22) Figure 5.”
BackgroundDas, B., Yeger, H., Tsuchida, R., Torkin, R., Gee, M. F. W., Thorner, P. S., Shibuya, M., Malkin, D., & Baruchel, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4575 · Cited by 131
The MYC Oncogene as a Cancer Drug Target
Hermeking, H. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481949 · Cited by 132
Strik, H., Deininger, M., Streffer, J., Grote, E., Wickboldt, J., Dichgans, J., Weller, M., & Meyermann, R. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.6.763 · Cited by 129
“indicating that the development of a more apoptosis resistant phenotype cannot only be a consequence of adjuvant radiochemotherapy but may reflect a natural process of selection. These findings are in line with two other features of glioblastoma: (1) most of these tumours show only a moderate response to adjuvant ther…”
ResultStress-mediated translational control in cancer cells
Leprivier, G., Rotblat, B., Khan, D., Jan, E., & Sorensen, P. H. B. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.11.002 · Cited by 145
Evaluation of microvascular density in tumors: pro and contra.
Nico, B., Benagiano, V., Mangieri, D., Maruotti, N., Vacca, A., & Ribatti, D. (2008) · PubMed · doi:10.14670/hh-23.601 · Cited by 133
Elas, M., Ahn, K., Parasca, A. D., Barth, E. D., Lee, D., Haney, C. R., & Halpern, H. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0446 · Cited by 140
Covalent and noncovalent modifiers of the p53 protein
Jayaraman, L., & Prives, C. L. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050271 · Cited by 150
Prognostic and predictive value of p53 and p21 in breast cancer
Elledge, R. M., & Allred, D. C. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006163101948 · Cited by 163
The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision
Matouk, I., Halle, D., Raveh, E., Gilon, M., Sorin, V., & Hochberg, A. (2015) · Oncotarget · doi:10.18632/oncotarget.6387 · Cited by 133
“This process can therefore facilitate the clonal expansion of cancer cells with compromised p53 function [51].”
BackgroundHypoxia activates Akt and induces phosphorylation of GSK-3 in PC12 cells
Beitner‐Johnson, D., Rust, R. T., Hsieh, T. ‐., & Millhorn, D. E. (2001) · Cellular Signalling · doi:10.1016/s0898-6568(00)00128-5 · Cited by 146
A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy
Post, D. E., & Meir, E. G. V. (2003) · Oncogene · doi:10.1038/sj.onc.1206464 · Cited by 146
“Such a novel vector appears ideally suited to target the hypoxic regions of tumors that are most resistant to apoptosis, and conventional radio- and chemotherapies (Graeber et al., 1996; Brown, 2000).”
BackgroundHyperbaric Oxygen Therapy for Malignancy: A Review
Daruwalla, J., & Christophi, C. (2006) · World Journal of Surgery · doi:10.1007/s00268-006-0190-6 · Cited by 129
“Hypoxic regions have also been correlated with reduced apoptotic potential of tumors with a highly malignant phenotype.(23,68) The cellular responses described above are adaptations tumor cells make as a result of oxygen deficiency.”
BackgroundInfluentialTargeting XBP-1 as a novel anti-cancer strategy
Koong, A. C., Chauhan, V., & Romero‐Ramírez, L. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2973 · Cited by 153
Albertella, M. R., Loadman, P. M., Jones, P. H., Phillips, R. M., Rampling, R., Burnet, N., Alcock, C., Anthoney, A., Vjaters, E., Dunk, C. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4020 · Cited by 127
Mittler, R., Shulaev, V., Seskar, M., & Lam, E. (1996) · The Plant Cell · doi:10.2307/3870407 · Cited by 131
Mitochondrial regulation of oxygen sensing
Bell, E. L., Emerling, B. M., & Chandel, N. S. (2005) · Mitochondrion · doi:10.1016/j.mito.2005.06.005 · Cited by 130
Tang, X., Lucas, J. E., Chen, J. L.-Y., LaMonte, G., Wu, J., Wang, M. C., Koumenis, C., & Chi, J.-T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2076 · Cited by 126
“For example, hypoxia enriches for tumor cells that lack p53 (46) and glucose deprivation selects for tumor cells that bear K-ras mutations (47).”
Differential, stage‐dependent expression of Hsp70, Hsp110 and Bcl‐2 in colorectal cancer
Hwang, T. S., Han, H. S., Choi, H. K., Lee, Y. J., KIM, Y., Han, M.-Y., & Park, Y. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.03011.x · Cited by 130
Candidate genes for the hypoxic tumor phenotype.
Koong, A. C., Denko, N. C., Hudson, K. M., Schindler, C., Swiersz, L. M., Koch, C., Evans, S. M., Ibrahim, H., Le, Q., Terris, D. J., et al. (2000) · PubMed · Cited by 140
Self-citationKhan, N. I., Williams, B. B., Hou, H. G., Li, H., & Swartz, H. M. (2007) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1635 · Cited by 131
“The presence of hypoxic cells in tumors, and their impact on the ability of radiotherapy to control tumor growth, has been demonstrated in numerous studies over the past decades (5, 14, 15, 21, 25, 45).”
Loss of Matrix Adhesion Triggers Rapid Transformation-Selective Apoptosis in Fibroblasts
McGill, G., Shimamura, A., Bates, R. C., Savage, R. E., & Fisher, D. E. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.4.901 · Cited by 131
“E1A/Ras-transformed p53 wild-type– or null MEF have served as a model of genetically related cell lines to examine the capacity of p53 to regulate apoptosis after treatment with chemotherapeutic agents, ionizing radiation, or hypoxia (Lowe et al., 1993a, 1994; Graeber et al., 1996).”
BackgroundMolecular Mechanism of Hypoxia-inducible Factor 1α-p300 Interaction
Gu, J., Milligan, J., & Huang, L. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009522200 · Cited by 130
Ide, T., Kitajima, Y., Miyoshi, A., Ohtsuka, T., Mitsuno, M., Ohtaka, K., Koga, Y., & Miyazaki, K. (2006) · International Journal of Cancer · doi:10.1002/ijc.22178 · Cited by 137
“Several studies have recently revealed that a hypoxic condition might select for more malignant cell clones.(21) Koong et al.”
BackgroundGlucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.
Brown, R. S., Leung, J. Y., Kison, P. V., Zasadny, K. R., Flint, A., & Wahl, R. L. (1999) · PubMed · Cited by 247
Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy
Belle, S. V., & Cocquyt, V. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(03)00093-3 · Cited by 129
“In vivo, hypoxic areas of solid tumour coincided with areas of decreased apoptosis [42].”
BackgroundInhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells
Babar, I., Czochor, J. R., Steinmetz, A., Weidhaas, J. B., Glazer, P. M., & Slack, F. J. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.10.17681 · Cited by 131
Anoxia Is Necessary for Tumor Cell Toxicity Caused by a Low-Oxygen Environment
Papandreou, I., Krishna, C., Kaper, F., Cai, D., Giaccia, A. J., & Denko, N. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3395 · Cited by 127
“The molecular trigger for this program is not known, but the intrinsic apoptotic pathway has been implicated (6, 7), with the tumor suppressor p53 sensitizing cells to hypoxic conditions (3).”
BackgroundSelf-citationLaderoute, K. R., Mendonca, H. L., Calaoagan, J. M., Knapp, A. M., Giaccia, A. J., & Stork, P. J. S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.18.12890 · Cited by 126
Self-citationRavi, R. K., & Bedi, A. (2002) · PubMed · Cited by 145
Becker, A., Hänsgen, G., Bloching, M. B., Weigel, C., Lautenschläger, C., & Dunst, J. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00182-5 · Cited by 127
Hyperbaric oxygen: does it promote growth or recurrence of malignancy?
Feldmeier, J. J., Carl, U. M., Hartmann, K. A., & Sminia, P. (2003) · PubMed · Cited by 153
Lesser, M. P., Farrell, J. H., & Walker, C. W. (2001) · Journal of Experimental Biology · doi:10.1242/jeb.204.1.157 · Cited by 143
Towards a method for automated classification of1H MRS spectra from brain tumours
Tate, A. R., Griffiths, J. R., Martínez-Pérez, I., Moreno, À., Barba, I., Cabañas, M. E., Watson, D. M., Alonso, J., Bartumeus, F., Isamat, F., et al. (1998) · NMR in Biomedicine · doi:10.1002/(sici)1099-1492(199806/08)11:4/5<201::aid-nbm508>3.0.co;2-6 · Cited by 126
Metadata
- Authors
- Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J.
- Affiliations
- Stanford Medicine (US)
- Howard Hughes Medical Institute (US)
- Massachusetts Institute of Technology (US)
- University of Pennsylvania (US)
- Cold Spring Harbor Laboratory (US)
- Venue
- Nature
- Published
- 1996-01
- Volume
- 379
- Issue
- 6560
- Pages
- 88-91
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2028999918
- Cited by
- 2,300
- References
- 31
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 16 · 2023: 30 · 2022: 27 · 2021: 55 · 2020: 39 · 2019: 37 · 2018: 37 · 2017: 51 · 2016: 56 · 2015: 56 · 2014: 41 · 2013: 70 · 2012: 78
- FWCI
- 52.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor hypoxia, apoptosis, solid tumors, p53, Bcl-2, p53 deficiency, tumor necrosis, tumor heterogeneity, tumor suppressor
- MeSH terms
- Animals, Cell Line, Transformed, Cell Transformation, Neoplastic, Neoplasm Transplantation, Neoplasms, Oxygen, Proto-Oncogene Proteins, Receptors, Estrogen, Tamoxifen, Cell Hypoxia, Genes, p53, Proto-Oncogene Proteins c-myc, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.